RxDoctor Payments Data

Christopher White, DO

Otolaryngology · Lewisburg, WVNPI 1306817689

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Optinose US, Inc. at 27.5% of the total. Reporting peaked in 2022 at $132 and has fallen 88.3% since, to $16 in 2023.

$453in general payments, 2019–2025

Across 26 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$125
  • Kaleo, Inc.$93
  • Regeneron Healthcare Solutions, Inc.$88
  • Stryker$70
  • Aerin Medical Inc.$34
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$17
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$453 in reported general payments places this provider in the 60th percentile of 48 otolaryngology providers in West Virginia.

See all otolaryngology providers in West Virginia

Medicare billing

Part B allowed, 2024
$138,855
Medicare patients
464
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate11$6,985
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth29$3,675
Fluticasone Propionate235$3,017
Ipratropium Bromide98$2,229
Levocetirizine Dihydrochloride301$1,988
Azelastine Hcl106$1,857
Fluocinolone Acetonide Oil34$1,411
Montelukast Sodium138$1,047
Mometasone Furoate14$996
Cephalexin77$938
Mupirocin102$737
Clotrimazole22$726
Gabapentin47$707
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$332
Clindamycin Hcl33$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$125$6,98511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 otolaryngology providers in West Virginia.

Other otolaryngology in Lewisburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →